Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Encouraging results presented on Advexin
January 5th, 2006
Introgen Therapeutics, Inc., (INGN) reported an update of data from its phase II trial evaluating Advexin combined with neoadjuvant chemotherapy and surgery in women with locally advanced breast cancer. Currently, after 35 months of follow-up, 92% of the treated patients are alive and 83% have survived without evidence of disease recurrence. Objective clinical responses were seen following the combined therapy in all of the patients with a median of 80% reduction in tumor size. Following tumor shrinkage, complete tumor removal by subsequent surgery was achieved in 100% of the patients. The results of the therapy with the addition of Advexin are better than what would be...
Source: Women's Health Weekly (2006-01-05)
|
